Literature DB >> 19384470

Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique.

Rong Zhao1, J Cory Kalvass, Gary M Pollack.   

Abstract

PURPOSE: To assess the blood-brain barrier (BBB) permeability of 12 clinically-used drugs in mdr1a(+/+) and mdr1a(-/-) mice, and investigate the influence of lipophilicity, nonspecific brain tissue binding, and P-gp-mediated efflux on the rate of brain uptake.
METHODS: The BBB partition coefficient (PS) was determined using the in situ mouse brain perfusion technique. The net brain uptake for 12 compounds, and the time course of brain uptake for selected compounds ranging in BBB equilibration kinetics from rapidly-equilibrating (e.g., alfentanil, sufentanil) to slowly-equilibrating (fexofenadine), was determined and compared.
RESULTS: There was a sigmoidal relationship in mdr1a(-/-) mice between the log-PS and clogD(7.4) in the range of 0-5. The brain uptake clearance was a function of both permeability and blood flow rate. The brain unbound fraction was inversely proportional to lipophilicity. Alfentanil achieved brain equilibrium approximately 4,000-fold faster than fexofenadine, based on the magnitude of PSxfu,brain.
CONCLUSIONS: In situ brain perfusion is a useful technique to determine BBB permeability. Lipophilicity, ionization state, molecular weight and polar surface area are all important determinants for brain penetration. The time to blood-to-brain equilibrium varies widely for different compounds, and is determined by a multiplicity of pharmacokinetic factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19384470     DOI: 10.1007/s11095-009-9876-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  38 in total

1.  Drug targeting. Breaking down barriers.

Authors:  Greg Miller
Journal:  Science       Date:  2002-08-16       Impact factor: 47.728

2.  The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid.

Authors:  B B BRODIE; H KURZ; L S SCHANKER
Journal:  J Pharmacol Exp Ther       Date:  1960-09       Impact factor: 4.030

3.  Transport of lead-203 at the blood-brain barrier during short cerebrovascular perfusion with saline in the rat.

Authors:  R Deane; M W Bradbury
Journal:  J Neurochem       Date:  1990-03       Impact factor: 5.372

Review 4.  The blood-brain barrier: bottleneck in brain drug development.

Authors:  William M Pardridge
Journal:  NeuroRx       Date:  2005-01

5.  Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition.

Authors:  J Cory Kalvass; Gary M Pollack
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

6.  Lipid solubility and drug penetration of the blood brain barrier.

Authors:  W H Oldendorf
Journal:  Proc Soc Exp Biol Med       Date:  1974-12

7.  Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Authors:  Kelly M Mahar Doan; Joan E Humphreys; Lindsey O Webster; Stephen A Wring; Larry J Shampine; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

8.  P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.

Authors:  Harunobu Tahara; Hiroyuki Kusuhara; Eiichi Fuse; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2005-04-08       Impact factor: 3.922

9.  Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice.

Authors:  J Cory Kalvass; Candace L Graff; Gary M Pollack
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

10.  Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration.

Authors:  Rong Zhao; J Cory Kalvass; Souzan B Yanni; Arlene S Bridges; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2008-12-29       Impact factor: 3.922

View more
  11 in total

1.  A new in situ brain perfusion flow correction method for lipophilic drugs based on the pH-dependent Crone-Renkin equation.

Authors:  Alex Avdeef; Na Sun
Journal:  Pharm Res       Date:  2010-11-02       Impact factor: 4.200

2.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

3.  A method to predict blood-brain barrier permeability of drug-like compounds using molecular dynamics simulations.

Authors:  Timothy S Carpenter; Daniel A Kirshner; Edmond Y Lau; Sergio E Wong; Jerome P Nilmeier; Felice C Lightstone
Journal:  Biophys J       Date:  2014-08-05       Impact factor: 4.033

4.  Direct evidence of abca1-mediated efflux of cholesterol at the mouse blood-brain barrier.

Authors:  Tuan Minh Do; Mélissa Ouellet; Frédéric Calon; Giovanna Chimini; Hélène Chacun; Robert Farinotti; Fanchon Bourasset
Journal:  Mol Cell Biochem       Date:  2011-06-10       Impact factor: 3.396

Review 5.  Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.

Authors:  Noora Sjöstedt; Hanna Kortejärvi; Heidi Kidron; Kati-Sisko Vellonen; Arto Urtti; Marjo Yliperttula
Journal:  Pharm Res       Date:  2014-01       Impact factor: 4.200

6.  Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer's disease.

Authors:  Dharmini C Mehta; Jennifer L Short; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2013-06-22       Impact factor: 4.200

7.  Physicochemical selectivity of the BBB microenvironment governing passive diffusion--matching with a porcine brain lipid extract artificial membrane permeability model.

Authors:  Oksana Tsinman; Konstantin Tsinman; Na Sun; Alex Avdeef
Journal:  Pharm Res       Date:  2010-10-14       Impact factor: 4.200

Review 8.  The blood-brain barrier: an engineering perspective.

Authors:  Andrew D Wong; Mao Ye; Amanda F Levy; Jeffrey D Rothstein; Dwight E Bergles; Peter C Searson
Journal:  Front Neuroeng       Date:  2013-08-30

9.  Does treatment of the laryngeal mucosa reduce dystonic symptoms? A prospective clinical cohort study of mannose binding lectin and other immunological parameters with diagnostic use of phonatory function studies.

Authors:  Mette Pedersen; Martin Eeg
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-05       Impact factor: 2.503

10.  Development of a physiologically-based pharmacokinetic model of the rat central nervous system.

Authors:  Raj K Singh Badhan; Marylore Chenel; Jeffrey I Penny
Journal:  Pharmaceutics       Date:  2014-03-18       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.